Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Cash & Equivalents (2016 - 2025)

CV Sciences (CVSI) has disclosed Cash & Equivalents for 14 consecutive years, with $278000.0 as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents changed N/A to $278000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $278000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $278000.0 for FY2025, N/A changed from the prior year.
  • Cash & Equivalents hit $278000.0 in Q4 2025 for CV Sciences, down from $381000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $5.2 million in Q1 2021 to a low of $278000.0 in Q4 2025.
  • Historically, Cash & Equivalents has averaged $1.3 million across 5 years, with a median of $1.0 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: surged 115.55% in 2023 and later tumbled 71.78% in 2024.
  • Year by year, Cash & Equivalents stood at $1.4 million in 2021, then plummeted by 55.56% to $611000.0 in 2022, then soared by 115.55% to $1.3 million in 2023, then decreased by 25.66% to $979000.0 in 2024, then crashed by 71.6% to $278000.0 in 2025.
  • Business Quant data shows Cash & Equivalents for CVSI at $278000.0 in Q4 2025, $381000.0 in Q3 2025, and $886000.0 in Q2 2025.